TABLE 1.
Characteristics of included studies.
| Study | Sex, strain, species | AD model | Main experimental groups (drugs dosage, route) | Intervention time | Duration of treatment |
|---|---|---|---|---|---|
| He et al. (2020) | Male Kunming mice | STZ model | C: CMC-Na, i.g. E: Tan IIA, 20/40/80 mg/kg, i.g. |
Immediately after injury | 28 days |
| Liao (2020) | Male SD rats | CCL2 model | C: NR E: Tan IIA, 25/50/75 mg/kg, i.g. |
3 days before CCL2 injury | 3 days |
| Liao et al. (2019) | Male SD rats | CCL2 model | C: NR E: Tan IIA, 25/50/75 mg/kg, i.g. |
3 days before CCL2 injury | 3 days |
| Mei et al. (2010) | Male and female APP/PS1 mice | APP/PS1 model | C: CMC-Na, i.g. E: CTS, 5/15/45 mg/kg, i.g. |
3 months of age | 16 weeks |
| Wan (2022) | Male APP/PS1 mice | APP/PS1 model | C: NR E: Tan IIA, 10/20 mg/kg, i.g. |
6 months of age | 8 weeks |
| Sheraz (2019) | Male SD rats | Aβ1-42 model | C: saline, i.g. E: Tan IIA, 20/40/80 mg/kg, i.g. |
Immediately after injury | 30 days |
| Fang et al. (2021) | Male ICR mice | LPS model | C: saline, i.p. E: Tan IIA, 1/5/10 mg/kg, i.p. |
1 day after LPS injected | 7 weeks |
| Mei et al. (2009) | APP/PS1 mice | APP/PS1 model | C: NR E: CTS, 5/15/30 mg/kg, p.o. |
3 months of age | 16 weeks |
| Ma et al. (2022) | APP/PS1 mice | APP/PS1 model | C: saline, i.p. E: Tan IIA, 10/20 mg/kg, i.p. |
12 months of age | 8 weeks |
| Xiang et al. (2024) | Male SD rats | STZ model | C: NR E: Tan IIA, 20/40/80 mg/kg, i.g. |
Immediately after injury | 24 days |
| He et al. (2020) | Male APP/PS1 mice | APP/PS1 model | C: saline, i.p. E: Tan IIA, 10/30 mg/kg, i.p. |
6 months of age | 30 days |
| Ding et al. (2020) | Male APP/PS1 mice | APP/PS1 model | C: saline, i.p. E: Tan IIA, 5/20 mg/kg, i.p. |
6 months of age | 30 days |
| Peng et al. (2022) | Male APP/PS1 mice | APP/PS1 model | C: saline, i.p. E: Tan IIA, 15/30 mg/kg, i.p. |
5 months of age | 30 days |
| Liu et al. (2016) | Male Swiss albino mice | STZ model | C: CMC-Na, i.g. E: Tan IIA, 20/40/80 mg/kg, i.g. |
1 h before STZ injectd | 28 days |
Abbreviations: LPS, lipopolysaccharide; SD, sprague dawley; CCL2, CC, chemokine ligand 2; STZ, streptozotocin; C, control group; E, experimental group; NR, no report; CMC-Na, sodium carboxymethyl cellulose; Tan IIA, tanshinone IIA; CTS, cryptotanshinone; i. g., intragastrically; i. p., intraperitoneally; p. o., per os.